Rofecoxib in migraine

References

• Stewart WF, Shechter A, Lipton RB. Migraine heterogeneity, disability, pain intensity, and attack frequency and duration. Neurology44(Supp 14), S24–S39 (1994).
   PubMed Web of Science ®Google Scholar
• Rasmussen BK. Epidemiology of headache. Cephalalgia15, 45–68 (1995).
   PubMed Web of Science ®Google Scholar
• Steward WF, Lipton RB, Simon D. Work- related disability: results from the American migraine study. Cephalalgia16, 231–238 (1996).
   Google Scholar
• Lipton RB, Stewart WF. Prevalence and impact of migraine. Neurol. Clin.15, 1–13 (1997).
   PubMed Web of Science ®Google Scholar
• Headache Classification Subcommittee of The International Headache Society. The International Classification of Headache Disorders. Second Edition. Cephalalgia24(Suppl. 1), 1–136 (2004).
   Web of Science ®Google Scholar
• Goadsby PJ, Edvinson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol.28, 183–187 (1990).
   PubMed Web of Science ®Google Scholar
• Olesen J, Friberg L, Olsen TS et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann. Neurol.28, 791–798 (1990).
   PubMed Web of Science ®Google Scholar
• Weiller C, May A, Limmroth V et al. Brain stem activation in spontaneous human migraine attacks. Nature Med.1, 658–660 (1981).
   Google Scholar
• Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligoemia and impaired activation of rCBF in classic migraine. Ann. Neurol.9, 344–352 (1995).
   Google Scholar
• Ebersberger A, Averbeck B, Messlinger K, Reeh PW. Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neuroscience89, 901–907 (1999).
   PubMed Web of Science ®Google Scholar
• Moskowitz MA, Macfarlane R. Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc. Brain Metab. Rev.5, 159–177 (1993).
   PubMedGoogle Scholar
• Blau JN, Dexter SL. The site of pain origin during migraine attacks. Cephalalgia1, 143–147 (1981).
   PubMed Web of Science ®Google Scholar
• Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain89(2–3), 107–110 (2001).
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Welch KMA. General principles of pharmacological treatment of migraine. In: The Headaches. Second Edition. Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Lippincott Williams & Wilkins, PA, USA, 385–389 (2000).
   Google Scholar
• Lance JW. Migraine prophylaxis - indication for drug therapy. In: Drug Treatment of Migraine and Other Headaches. Diener HC (Ed.). Karger, Basel, Switzerland, 250–255 (2000).
   Google Scholar
• Silberstein SD, Saper JR, Freitag FG. Migraine: diagnosis and treatment. In: Wolff’s Headache and Other Head Pain. Seventh Edition. Silberstein SD, Lipton RB, Dalessio DJ (Eds). Oxford University Press, NY, USA, 121–246 (2001).
   Google Scholar
• Mathew NT, Silberstein SD. Anticonvulsants in migraine prophylaxis. In: Drug Treatment of Migraine and Other Headaches. Diener HC (Ed.). Karger, Basel, Switzerland, 288–298 (2000).
   Google Scholar
• Dodick DW. Acute and prophylactic management of migraine. Clin. Cornerstone4, 36–52 (2001).
   PubMedGoogle Scholar
• Tfelt-Hansen P, Lipton RB. Prioritizing treatment. In: The Headaches. Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Raven Press, NY, USA, 359–362 (1993).
   Google Scholar
• Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N. Engl. J. Med.346, 257–270 (2002).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Stewart WF, Cady R et al. 2000 Wolff Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache40, 783–791 (2000).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache42(Suppl. 1), 3–9 (2002).
   PubMed Web of Science ®Google Scholar
• Saxena P, Tfelt-Hansen P. Triptans, 5- HT1B/1D receptor agonists in the acute treatment of Migraine. In: The Headaches. Second Edition. Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Lippincott Williams & Wilkins, PA, USA, 411–438 (2000).
   Google Scholar
• Peroutka SJ. Beyond monotherapy: rational polytherapy in migraine. Headache38, 18–22 (1998).
   PubMedGoogle Scholar
• Bates D, Ashford E, Dawson R et al. Subcutaneous sumatriptan during the migraine aura. Neurology44, 1587–1592 (1994).
   PubMed Web of Science ®Google Scholar
• Visser WH, de Vriend RH, Jaspers NHWM, Ferrari MD. Sumatriptan – nonresponders: a survey in 366 migraine patients. Headache36, 471–475 (1996).
   PubMed Web of Science ®Google Scholar
• Dahlof CG. How does sumatriptan perform in clinical practice? Cephalalgia15(Suppl. 15), 21–28 (1995).
   PubMedGoogle Scholar
• Visser WH, de Vriend RH, Jaspers NHWM, Ferraria MD. Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology47, 46–51 (1996).
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, McEwen J. Nonsteroidal anti-inflammatory drugs in the acute treatment of migraine. In: The Headaches. Second Edition. Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Lippincott Williams & Wilkins, PA, USA, 391–397 (2000).
   Google Scholar
• Limmroth V, Przywara S. Analgesics. In: Drug Treatment of Migraine and Other Headaches. Diener HC (Ed.). Monogr. Clin. Neurosci.17, 30–43 (2000).
   Google Scholar
• Krymchantowski AV, Silva MT. Intravenous lysine clonixinate for the acute treatment of severe migraine attacks: a double-blind, randomized, placebo- controlled study. Curr. Ther. Res.64, 505–513 (2003).
   Google Scholar
• Ferrari MD, James MH, Bates D et al. Oral sumatriptan: possible benefit of a second dose, and incidence and treatment of headache recurrences. Cephalalgia14, 330–338 (1994).
   PubMed Web of Science ®Google Scholar
• Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia22, 309–312 (2002).
   PubMed Web of Science ®Google Scholar
• Masferrer JL, Isakson PC, Seibert K. Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol. Clin. North Am.25, 363–372 (1996).
   PubMed Web of Science ®Google Scholar
• Langman MJ, Jensen DM, Watson DJ et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA282, 1929–1933 (1999).
   PubMed Web of Science ®Google Scholar
• Silberstein S, Tepper S, Brandes J et al. Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology62(9), 1552–1557 (2004).
   PubMedGoogle Scholar
• Lance JW. Headache. Ann. Neurol.10, 1–10 (1981).
   PubMed Web of Science ®Google Scholar
• Wilkinson M. Treatment of the acute migraine attack - current status. Cephalalgia3, 61–67 (1983).
   PubMedGoogle Scholar
• Krymchantowski AV, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurology4(1), 10 (2004).
   PubMed Web of Science ®Google Scholar
• Vapaatalo H. Tolfenamic acid and migraine - aspects on prostaglandins and leukotrienes. Pharmacol. Toxicol.75(Suppl. II), 76–80 (1994).
   Google Scholar
• The Diclofenac-K/Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac- potassium, in comparison to oral sumatriptan and placebo. Cephalalgia19, 232–240 (1999).
   PubMed Web of Science ®Google Scholar
• Diener HC, Limmroth V. Analgesics. Curr. Med. Res. Opin.17(Suppl. 1), S13–S16 (2001).
   PubMedGoogle Scholar
• Rasmussen M-JK, Binzer M. Non-steroidal anti-inflammatory drugs in the treatment of migraine. Curr. Med. Res. Opin.17(Suppl. 1), S26–S29 (2001).
   PubMedGoogle Scholar
• Geraud G, Compagnon A, Rossi A, on behalf of the COZAM Study Group. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. Eur. Neurol.47, 88–98 (2002).
   PubMed Web of Science ®Google Scholar
• Dib M, Massiou H, Weber M et al. Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial. Neurology58, 1660–1665 (2002).
   PubMedGoogle Scholar
• Matheson AJ, Figgitt DP. Rofecoxib. Drugs61(6), 833–865 (2001).
   PubMed Web of Science ®Google Scholar
• Vioxx. Vioxx. USPC in PDR (2004).
   Google Scholar
• Gottesdiener K, Agrawal N, Porras A et al. Effects of renal insufficiency and hemodialysis on the pharmacokinetics of rofecoxib. Am. J. Ther.10(4), 252–258 (2003).
   Google Scholar
• Silberstein S, Tepper S, Brandes J et al. Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology62, 1552–1557 (2004).
   PubMedGoogle Scholar
• MRL MK-0966–162 clinical study reports on file.
   Google Scholar
• Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia22(8), 633–658 (2002).
   PubMed Web of Science ®Google Scholar
• Krymchantowski AV. Acute treatment of migraine. Breaking the paradigm of monotherapy. BMC Neurol.4(1), 4 (2004).
   PubMed Web of Science ®Google Scholar